Reduction of Pulmonary Artery Pressure in Patients Subjected to Cardiac Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to assess the ability of clonidine to reduce the mean pulmonary artery pressure in patients with pulmonary hypertension subjected to cardiac surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Anesthesia |
Drug: Clonidine Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Intravenous Clonidine Does Not Reduce Pulmonary Artery Pressure in Patients Subjected to Cardiac |
- Reduction pulmonary artery pressure [ Time Frame: During intraoperative (hours) ] [ Designated as safety issue: Yes ]Assessed four times: before (T0) administration of 2 μg·kg-1 of intravenous clonidine or a placebo, 30 minutes after the onset of treatment (T1), immediately after ECC (T2), and 10 minutes after the injection of protamine (T3).
- Doses of Dobutamine [ Time Frame: During intraoperative (hours) ] [ Designated as safety issue: Yes ]Evaluate the need for using and dose of dobutamine immediately after extracorporeal circulation between groups.
- Doses of Sodium nitroprusside [ Time Frame: During intraoperative (hours) ] [ Designated as safety issue: Yes ]Evaluate the need for using and dose of sodium nitroprusside immediately after extracorporeal circulation between groups.
| Enrollment: | 29 |
| Study Start Date: | March 2009 |
| Study Completion Date: | March 2012 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Sham Comparator: Clonidine
Administration of 2 μg/kg of intravenous clonidine.
|
Drug: Clonidine
Administration of 2 μg/kg of intravenous clonidine
|
|
Placebo Comparator: Placebo
Injection of placebo solution.
|
Drug: Placebo
Injection of placebo solution.
|
Detailed Description:
Prospective, clinical-interventionist, randomized, and double-blind study. Patients with group 2 pulmonary hypertension will be included and subjected to cardiac surgery with extracorporeal circulation. Mean pulmonary artery pressure and the doses of dobutamine and sodium nitroprusside will be assessed four times: before (T0) administration of 2 μg/kg of intravenous clonidine or a placebo, 30 minutes after the onset of treatment (T1), immediately after extracorporeal circulation (T2), and 10 minutes after the injection of protamine (T3).
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signing an informed consent form,
- Aged 18 to 80 years
- Pulmonary hypertension due to left heart disease,
- Physical status 2 or 3 according to the classification system of the American Society of Anesthesiologists,
- Subjected to cardiac circulation with extracorporeal circulation
Contacts and Locations| Brazil | |
| Luiz Fernando dos Reis Falcao | |
| Sao Paulo, SP, Brazil, 04024-002 | |
| Study Chair: | Luiz Fernando R Falcao, Ph.D. | Federal University of Sao Paulo |
| Principal Investigator: | Benedito B Joao, MD | Federal University of São Paulo |
More Information
No publications provided
| Responsible Party: | Luiz Fernando dos Reis Falcao, Clinical Professor, Federal University of São Paulo |
| ClinicalTrials.gov Identifier: | NCT01597427 History of Changes |
| Other Study ID Numbers: | UNIFESP-02 |
| Study First Received: | May 8, 2012 |
| Last Updated: | May 10, 2012 |
| Health Authority: | Brazil: Ethics Committee |
Keywords provided by Federal University of São Paulo:
|
Clonidine Hypertension Pulmonary Cardiac Surgical Procedures |
Additional relevant MeSH terms:
|
Clonidine Antihypertensive Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Sympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics Sensory System Agents Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 16, 2013